Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer
10.3390/cancers11060737
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Review |
| Published: |
MDPI AG
2021
|
| Subjects: | |
| Online Access: | https://scholarbank.nus.edu.sg/handle/10635/210771 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | National University of Singapore |
| id |
sg-nus-scholar.10635-210771 |
|---|---|
| record_format |
dspace |
| spelling |
sg-nus-scholar.10635-2107712024-04-02T07:44:26Z Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer Collins, D.M. Conlon, N.T. Kannan, S. Verma, C.S. Eli, L.D. Lalani, A.S. Crown, J. BIOLOGICAL SCIENCES Breast cancer HER2 Lapatinib Neratinib Tyrosine kinase inhibitors 10.3390/cancers11060737 Cancers 11 6 737 2021-12-16T07:49:11Z 2021-12-16T07:49:11Z 2019 Review Collins, D.M., Conlon, N.T., Kannan, S., Verma, C.S., Eli, L.D., Lalani, A.S., Crown, J. (2019). Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer. Cancers 11 (6) : 737. ScholarBank@NUS Repository. https://doi.org/10.3390/cancers11060737 20726694 https://scholarbank.nus.edu.sg/handle/10635/210771 Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/ MDPI AG Scopus OA2019 |
| institution |
National University of Singapore |
| building |
NUS Library |
| continent |
Asia |
| country |
Singapore Singapore |
| content_provider |
NUS Library |
| collection |
ScholarBank@NUS |
| topic |
Breast cancer HER2 Lapatinib Neratinib Tyrosine kinase inhibitors |
| spellingShingle |
Breast cancer HER2 Lapatinib Neratinib Tyrosine kinase inhibitors Collins, D.M. Conlon, N.T. Kannan, S. Verma, C.S. Eli, L.D. Lalani, A.S. Crown, J. Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| description |
10.3390/cancers11060737 |
| author2 |
BIOLOGICAL SCIENCES |
| author_facet |
BIOLOGICAL SCIENCES Collins, D.M. Conlon, N.T. Kannan, S. Verma, C.S. Eli, L.D. Lalani, A.S. Crown, J. |
| format |
Review |
| author |
Collins, D.M. Conlon, N.T. Kannan, S. Verma, C.S. Eli, L.D. Lalani, A.S. Crown, J. |
| author_sort |
Collins, D.M. |
| title |
Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| title_short |
Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| title_full |
Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| title_fullStr |
Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| title_full_unstemmed |
Preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: Implications for the treatment of HER2- positive and HER2-mutated breast cancer |
| title_sort |
preclinical characteristics of the irreversible pan- her kinase inhibitor neratinib compared with lapatinib: implications for the treatment of her2- positive and her2-mutated breast cancer |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://scholarbank.nus.edu.sg/handle/10635/210771 |
| _version_ |
1795301680002105344 |